(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Steinmeier honours Italian 'guest workers' who rebuilt German economy- Tech for Wellbeing: Applications and Devices for a Better You
- The Best 15 Applications for Efficiency and Association
- Farmers call for French blockades over cow disease cull
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- A definitive Burger Confrontation: Which One Rules?
- The 15 Most Powerful Forerunners in Business
- A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
- Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
